Cabazitaxel Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0007 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/07/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
29/06/2023 
SmPC 
Veterinary Medicinal Products - Other variation 
IA/0006 
B.II.e.3.b - Change in test procedure for the 
12/05/2023 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
IB/0004 
C.I.11.z - Introduction of, or change(s) to, the 
11/01/2023 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/476/2
Periodic Safety Update EU Single assessment - 
24/02/2022 
24/05/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
02106 
cabazitaxel 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/476/202106. 
IB/0003 
C.I.2.a - Change in the SPC, Labelling or PL of a 
29/03/2022 
24/05/2022 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0002 
A.7 - Administrative change - Deletion of 
26/01/2022 
24/05/2022 
Annex II and 
manufacturing sites 
PL 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
